Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: Review of cutaneous and mucosal side effects of mTOR inhibitors

Dermatology

Volumn 223, Issue 1, 2011, Pages 4-8

  De Masson, A ^a   Fouchard, N ^a   Mery Bossard L ^a   Dauendorffer, J N ^a  

^a Department of Dermatology   (France)

Author keywords

Mammalian target of rapamycin; Renal cell carcinoma; Temsirolimus

Indexed keywords

BEVACIZUMAB; CLOBETASOL PROPIONATE; COLCHICINE; DIFLUCORTOLONE VALERATE; EVEROLIMUS; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; AGED; APHTHOUS STOMATITIS; CANCER GROWTH; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SCROTAL PAIN; SCROTUM DISORDER; SKIN ULCER;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; GENITAL DISEASES, MALE; HUMANS; KIDNEY NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; SCROTUM; SIROLIMUS; STOMATITIS, APHTHOUS; TOR SERINE-THREONINE KINASES;

EID: 80053978781     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000329902     Document Type: Review

References (30)

1. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. (Pubitemid 46849157)
2. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
3. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66: 5549-5554. (Pubitemid 43927103)
4. Hidalgo M, Buckner JC, Erlichman C, et al: A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006; 12: 5755-5763. (Pubitemid 44629606)
5. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19: 1387-1392.
6. Campistol JM, de Fijter JW, Flechner SM, et al: mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010; 24: 149-156.
7. Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245. (Pubitemid 12149145)
8. Katz J, Langevitz P, Shemer J, et al: Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Am Acad Dermatol 1994; 31: 459-461. (Pubitemid 24273317)
9. Fontes V, Machet L, Huttenberger B, et al: Recurrent aphthous stomatitis: treatment with colchicine: an open trial of 54 cases. Ann Dermatol Venereol 2002; 129: 1365-1369. (Pubitemid 36287811)
10. Scully C: Clinical practice: aphthous ulceration. N Engl J Med 2006; 355: 165-172.
11. Choi YL, Kim JA, Jang KT, et al: Characteristics of cutaneous cytomegalovirus infection in non-acquired immune deficiency syndrome, immunocompromised patients. Br J Dermatol 2006; 155: 977-982.
12. Abraham RT, Gibbons JJ: The mammalian target of rapamycin signalling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13: 3109-3114. (Pubitemid 46944891)
13. Figlin RA: Mechanisms of disease: Survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol 2008; 5: 601-609.
14. Javier AF, Bata-Csorgo Z, Ellis CN, et al: Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G 1 phase in human keratinocyte stem cells. J Clin Invest 1997; 99: 2094-2099. (Pubitemid 27203765)
15. Duncan JI: Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. J Invest Dermatol 1994; 102: 84-88. (Pubitemid 24039568)
16. Reitamo S, Spuls PI, Sassolas B, et al, for the Sirolimus European Psoriasis Study Group: Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145: 438-445. (Pubitemid 32953701)
17. Schäffer M, Schier R, Napirei M, Michalski S, Traska T, Viebahn R: Sirolimus impairs wound healing. Langenbecks Arch Surg 2007; 392: 297-303. (Pubitemid 46675809)
18. Dormond O, Contreras AG, Meijer E, et al: CD40-induced signaling in human endothelial cells results in mTORC2-and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol 2008; 181: 8088-8095.
19. Mahe E, Morelon E, Lechaton S, et al: Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476-482. (Pubitemid 40280181)
20. Van Gelder T, ter Meulen C, Hené R, Weimar W, Hoitsma A: Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788-791. (Pubitemid 36373448)
21. Warino L, Libecco J: Cutaneous effects of sirolimus in renal transplant recipients. J Drugs Dermatol 2006; 5: 273-274.
22. Fasolo A, Sessa C: mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008; 17: 1717-1734.
23. Vignot S, Faivre S, Aquirre D, et al: mTORtargeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-527.
24. Chuang P, Langone AJ: Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007; 7: 714-717. (Pubitemid 46376460)
25. Sullivan TP, King LE Jr, Boyd AS: Colchicine in dermatology. J Am Acad Dermatol 1998; 39: 993-999. (Pubitemid 28547734)
26. Epailly E, Lorho R: Side effects of proliferation signal inhibitors and their management. Gastroenterol Clin Biol 2009; 33: 268-274.
27. Kahan BD, for the Rapamune US Study Group: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194-202. (Pubitemid 30446974)
28. Dereure O: Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opin Drug Saf 2003; 2: 467-473.
29. Motzer RJ, Escudier B, Oudard S, et al, RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
30. Ravaud A: Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011; 16(suppl 2):32-44.